Financial Data and Key Metrics Changes - The fourth quarter revenue was $983 million, representing a decline of 10.9% year-over-year, largely impacted by foreign currency and a stronger US dollar [19] - Organic sales decreased by 2.6%, but excluding China, sales grew by 0.4% [19] - Adjusted EPS in the fourth quarter was $0.46, exceeding the high end of the outlook range by $0.09, but declined by $0.37 year-over-year [21] - Operating income was $154 million with an operating margin of 15.7%, which contracted year-over-year due to FX and inflation headwinds [20] Business Line Data and Key Metrics Changes - Organic sales in the Technologies & Equipment (T&E) segment declined by 2.2%, while the consumables segment declined by 3.4% [23] - Aligners grew over 25% in the fourth quarter, driven by strong growth in both SureSmile and Byte [24] - The Equipment & Instruments business declined by low single digits, while implants were down double digits due to softer demand in China, the US, and Europe [26] Market Data and Key Metrics Changes - US sales were $369 million, representing an organic sales decline of 1.7% [28] - European sales were down 3.2% on an organic basis due to lower implants and equipment volume [29] - In China, lower sales were experienced across product groups due to COVID shutdowns and VBP impacts [30] Company Strategy and Development Direction - The company announced an organizational restructuring plan aimed at improving operational performance and aligning business units [10] - The plan includes reducing the global workforce by approximately 8% to 10% and implementing five global business units [12] - The company aims to achieve at least $200 million in annual cost savings over the next 18 months [14] Management's Comments on Operating Environment and Future Outlook - Management views 2023 as a transition year with significant work underway to improve the company and fix internal issues [35] - The company expects organic sales to be in the range of down 1% to up 2% for 2023, with a net sales range of $3.85 billion to $3.95 billion [36] - Management remains cautious about the demand outlook in China due to significant uncertainties [39] Other Important Information - The company plans to return at least 50% of free cash flow to shareholders through dividends and share repurchases [50] - A 12% increase in dividends was announced, marking three consecutive years of double-digit increases [34] - The company maintains a strong balance sheet with $365 million in cash and cash equivalents and a net debt-to-EBITDA ratio of approximately 2.1 times [33] Q&A Session Summary Question: Revenue expectations and growth rates - Management has not laid out long-term revenue expectations but anticipates returning to market growth rates above 2.5% to 3% in the coming years [68] Question: Timeline for new investments and product launches - The reorganization provides better visibility on R&D investments and their returns, with expectations for more disciplined spending moving forward [75] Question: Current market conditions in major geographies - Management is more positive about Q1 than previously, expecting strong growth from the Ortho portfolio and CAD/CAM, despite headwinds in China [78][80] Question: Impact of SKU rationalization on sales - No meaningful SKU rationalization is expected in 2023, with plans to be laid out for future actions [101] Question: Margin profile of Wellspect business - The Wellspect business is included in full-year expectations and is accretive to overall corporate average [105]

Fourth Quarter 2022 Earnings and 2023 Outlook February 28, 2023 2 Forward-Looking Statements and Associated Risks This Presentation contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the expected timing, benefits and costs associated with the Company's restructuring plan described in this Presentation. The Company's forward-looking statements represent current e ...

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Andrea Daley - VP, IR Simon Campion - Chief Executive Officer Glenn Coleman - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Elizabeth Anderson - Evercore Nathan Rich - Goldman Sachs Erin Wright - Morgan Stanley Brandon Couillard - Jefferies Jeffrey Johnson - Baird Daniel Clark - Bank of America Jonathan Block - Stifel Michael Petusky - Barrington Research Jason ...

4 " " Third Quarter 2022 Earnings Conference Call November 14, 2022 2 Forward-Looking Statements and Associated Risks All statements in this presentation that do not directly and exclusively relate to historical facts constitute "forward-looking statements." These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-16211 DENTSPLY SIRONA Inc. | Title of each class Common Stock, par value $.01 per share | | | | --- | --- | --- | | | Trading Symbol | Name ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____ to_____ Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer inc ...

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Andrea Daley - VP, IR John Groetelaars - Interim CEO Barbara Bodem - CFO Conference Call Participants Elizabeth Anderson - Evercore Kevin Caliendo - UBS Jason Bednar - Piper Sandler Erin Wright - Morgan Stanley Jeff Johnson - Baird Jon Block - Stifel Matt Miksic - Credit Suisse Rachel Vatnsdal - JPMorgan Operator Welcome to the Dentsply Sirona First Quarter 2022 Results Conference Call. All parti ...

First Quarter 2022 Earnings Conference Call May 10, 2022 2 Forward-Looking Statements and Associated Risks All statements in this presentation that do not directly and exclusively relate to historical facts constitute "forward-looking statements." These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause ...

Financial Performance - Dentsply Sirona reported revenues of $4.25 billion for 2021, reflecting a 24.6% organic growth compared to 2020 and a 4.9% increase compared to 2019 [12][23] - For Q4 2021, revenue was $1.088 billion, with organic sales growth of 1.8% and reported growth of 0.6% [15] - The operating margin for 2021 was 20.5%, with adjusted EPS at $2.87, and operating cash flow of $657 million [12][28] Business Segment Performance - In Q4, technology and equipment organic sales grew by 6.5%, while consumables declined by 4.6% [19] - Clear aligners, implants, and CAD/CAM businesses showed strong growth despite supply chain challenges [15][19] - The full year 2021 saw clear aligners generating $270 million, with SureSmile exceeding the $100 million annual run rate goal [24] Market Performance - U.S. sales in Q4 were $385 million, with slight organic growth year-on-year, while European sales were $437 million with 1.8% organic growth [22] - The rest of the world sales reached $266 million, representing 4% organic growth, impacted by COVID restrictions in APAC, particularly China [22] Company Strategy and Industry Competition - The company aims for reliable 4% to 5% revenue growth, continuous margin improvement, and double-digit earnings growth [40] - Dentsply Sirona is focusing on digital dentistry, with significant investments in R&D and strategic collaborations, such as with Google Cloud [11][45] - The company is committed to enhancing its digital portfolio and improving operational efficiencies while navigating supply chain challenges [35][53] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing supply chain constraints and anticipated challenges for at least one or two quarters in 2022 [15][30] - The effective tax rate is expected to be between 23% and 24%, with EPS projected in the range of $3.05 to $3.25 for 2022 [31][31] - Management expressed confidence in the resilience of the dental market and the company's ability to expand revenue and earnings over time [36][56] Other Important Information - The company plans to return at least 50% of free cash flow to shareholders through dividends and share repurchases [35] - Dentsply Sirona is developing global standards for cleft treatment protocols and sponsoring the 2022 World Oral Health Campaign [37] Q&A Session Summary Question: Impact of Omicron on Q4 results and January performance - Management noted that December saw complications due to staffing shortages, leading to lower volumes, which continued into January, particularly in regions with strict COVID policies [60][61] Question: Commercial launch calendar for Primeprint - The global launch is expected towards the end of Q2, primarily in North America and Central Europe, with further details to be refined as the launch date approaches [63][66] Question: Supply chain disruptions and visibility on components - Management indicated that visibility into electronic component shortages is complicated, with expectations that issues may persist into the first half of the year [71][73] Question: Confidence in supply chain improvement in the second half - Management expressed cautious optimism based on supplier feedback and ongoing efforts to manage inventory levels [110] Question: Strategy regarding portfolio evolution - The company continues to evaluate its portfolio based on growth potential, margin accretion, and alignment with digital workflows, with no immediate plans for major divestitures [88]